<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26310">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764229</url>
  </required_header>
  <id_info>
    <org_study_id>LYC-30937-2002</org_study_id>
    <secondary_id>2016-003633-26</secondary_id>
    <nct_id>NCT02764229</nct_id>
  </id_info>
  <brief_title>Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis</brief_title>
  <official_title>A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lycera Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lycera Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to allow subjects completing study LYC-30937-2001 the
      opportunity to receive LYC-30937-EC 25 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who complete the 8 week treatment period of the double-blind, placebo-controlled
      study LYC-30937-2001 will have the option of receiving LYC-30397-EC 25 mg PO QD in this
      open-label extension study (LYC-30937-2002). Subjects meeting eligibility criteria will
      enter this open-label extension trial upon completion of the LYC-30937-2001 Week 8 study
      procedures. This open-label extension study will consist of 44 weeks of treatment followed
      by a 2 weeks post-treatment follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and type of adverse events (AEs), serious adverse events and AEs that led to discontinuation of treatment</measure>
    <time_frame>46 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Mayo stool frequency subscore at Week 4, 8, 20, 32 and 44 as compared to the Study LYC-30937-2001 Week 8 stool frequency subscore</measure>
    <time_frame>Week 4, 8, 20, 32 and 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Mayo rectal bleeding subscore at Week 4, 8, 20, 32 and 44 as compared to the study LYC-30937-2001 Week 8 rectal bleeding subscore</measure>
    <time_frame>Week 4, 8, 20, 32 and 44</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>LYC-30937-EC 25 mg PO QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYC-30937-EC 25 mg by mouth once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYC-30937-EC</intervention_name>
    <arm_group_label>LYC-30937-EC 25 mg PO QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed the 8-week double-blind treatment period of study LYC-30937-2001

          -  Male and females of childbearing potential must agree to use adequate birth control
             during the study and for 30 days after discontinuing study drug

          -  Non-pregnant, non-lactating females who are not planning to become pregnant while
             enrolled in this study

          -  Investigator considers it safe and potentially beneficial to participate

          -  Ability to provide written informed consent and to be compliant with study schedule

        Exclusion Criteria:

          -  Subjects who completed study LYC-30937-2001, but who experienced a serious adverse
             event that was considered related to investigational product, has an unstable medical
             condition, or for any other reason in the opinion of the investigator should not
             participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Jeffrey Wilkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lycera Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Goodrich, MS</last_name>
    <phone>734-233-3161</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Lycera investigational site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lycera investigational site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>May 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
